1007884-59-4

Upstream product

• 1007882-12-3 (S)-tert-butyl 2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1228552-27-9 ((S)-1-{(S)-2-[5-(4-bromophenyl)-1H-imidazol-2-yl]pyrrolidine-1-carbonyl}-2-methylpropyl)carbamic acid methyl ester 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 1007881-98-2 y 
• 1255936-24-3 (S)-5-(4-bromophenyl)-2-(pyrrolidin-2-yl)-1H-imidazole 
• 1007882-39-4 (S)-benzyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 99-73-0 para-bromophenacyl bromide 
• 1007882-04-3 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1007882-40-7 benzyl tert-butyl (2S,2'S)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate) 
• 72-18-4 L-valine 

Downstream Products

• 1331932-07-0 C₅₆H₆₃N₉O₈ 
• 1331932-09-2 C₄₁H₅₃N₉O₆ 
• 1007884-60-7 methyl N-[(2S)-3-methyl-1-oxo-1-[(2S)-2-{5-[4-(4-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]butan-2-yl]carbamate 

Relevant academic research and scientific papers

Daclatasvir hydrochloride impurity hydrochloride, preparation method and application thereof

The invention discloses daclatasvir hydrochloride impurity hydrochloride, a preparation method and application thereof, wherein the structure of the daclatasvir hydrochloride impurity is represented by a formula (I). The preparation method comprises the f

Monoglycosyl-containing heterocyclic compound for inhibiting hepatitis C viruses and preparation method

The invention discloses a monoglycosyl-containing heterocyclic compound for inhibiting hepatitis C viruses and a preparation method. The monoglycosyl-containing heterocyclic compound has a chemical structure represented by a formula I shown in the description. The monoglycosyl-containing heterocyclic compound disclosed by the invention can be used for effectively inhibiting protease of the hepatitis C viruses and treating infection of the hepatitis C viruses (HCV).

ANTIVIRAL AGENTS

The present invention relates to antiviral compounds of formula (I), compositions containing these compounds, processes for their preparation, intermediates in their synthesis, and their use as therapeutics for prevention of organ transplantation rejection, the treatment of immune disorders and inflammation, and treatment of viral (particularly hepatitis C viral) infection.